Ling Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ling Guo has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Chengcong Chen
Affiliation Department of Radiation Oncology, Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, China
1 shared publication- Chris Kafai Li
Janssen Res & Dev, SFBC, 1600 Sierra Point Pkwy, Brisbane, CA 94005 USA
1 shared publication - Chunhua Wen
State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China
1 shared publication - Chunxiu Zhong
State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China
1 shared publication - Deke Jiang
State Key Laboratory of Organ Failure Research, Guangdong Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases and Hepatology Unit, Institutes of Liver Diseases Research of Guangdong Province, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
1 shared publication Guoxin Hu
Affiliations Department of Infectious Diseases, Peking University Shenzhen hospital, Shenzhen, China, Clinical Institute of Anhui Medical University & Peking University Shenzhen hospital, Shenzhen, China
1 shared publication
Latest Publications
- Open Access
- 9 September 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (9) , e0356638
Identification and validation of oxidative stress-related immune signatures in Hepatitis B Virus associated acute liver failure based on WGCNA and machine learning
Background: Acute liver failure (ALF) is a serious clinical disease. Immune infiltration and oxidative stress (OS) play an important role in ALF, but the combination of oxidative stress and immune infiltration in ALF has not been explored. Methods: Differential expression analysis and weighted gene co-expression network analysis (WGCNA) were performed on ALF and control samples in the GSE96851 dataset to obtain DE-OS-MGs. Candidate OS-IM-associated signature genes were mined using the least absolute shrinkage and selection operator (LASSO) and support vector machine (SVM) machine learning. Finally, OS-IM-related signature genes were obtained by expression analysis and ROC validation. Single gene set enrichment analysis (GSEA), TF-miRNA-mRNA network construction and drug prediction were also performed for OS-IM-related signature genes. Results: Differential analysis identified a total of 3580 DEGs in ALF and control samples, and differential analysis of immune cells yielded 15 immune cell species that were significantly different between the two groups. After WGCNA analysis, 1134 key module genes were screened. Then, 3580 DEGs, 855 OS-related genes, and 1134 key module genes were intersected, resulting in a total of 89 DE-OS-MGs. Furthermore, machine learning was performed and the genes were intersected to obtain 5 candidate OS-IM-related signature genes. The expression levels and ROC analysis of the 5 genes were validated in the GSE96851 and GSE120652 datasets, and 4 genes (CLU, APOH, AMBP, and GPX8) were used as biomarkers (OS-IM-related signature genes) for subsequent analysis. Single-gene GSEA enrichment analysis revealed that the 4 biomarkers were associated with metabolic processes. A miRNA-mRNA network with 123 nodes and 194 relationship pairs was obtained. 49 TFs of 3 biomarkers (APOH, AMBP, and GPX8) and 56 relationship pairs of TFs-mRNA regulatory network also constructed. Searching for therapeutic drugs of 4 biomarkers, a drug-mRNA network of CLU and 3 drugs was constructed. Conclusion: In this study, we combined immune infiltration landscape and oxidative stress based on bioinformatic analysis to screen for diagnostic markers (CLU, APOH, AMBP, and GPX8) of ALF. It provides a new idea and theoretical basis for the therapeutic diagnosis of ALF.
- 9 September 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (9) , e0356638
Open AccessIdentification and validation of oxidative stress-related immune signatures in Hepatitis B Virus associated acute liver failure based on WGCNA and machine learning
Background: Acute liver failure (ALF) is a serious clinical disease. Immune infiltration and oxidative stress (OS) play an important role in ALF, but the combination of oxidative stress and immune infiltration in ALF has not been explored. Methods: Differential expression analysis and weighted gene co-expression network analysis (WGCNA) were performed on ALF and control samples in the GSE96851 dataset to obtain DE-OS-MGs. Candidate OS-IM-associated signature genes were mined using the least absolute shrinkage and selection operator (LASSO) and support vector machine (SVM) machine learning. Finally, OS-IM-related signature genes were obtained by expression analysis and ROC validation. Single gene set enrichment analysis (GSEA), TF-miRNA-mRNA network construction and drug prediction were also performed for OS-IM-related signature genes. Results: Differential analysis identified a total of 3580 DEGs in ALF and control samples, and differential analysis of immune cells yielded 15 immune cell species that were significantly different between the two groups. After WGCNA analysis, 1134 key module genes were screened. Then, 3580 DEGs, 855 OS-related genes, and 1134 key module genes were intersected, resulting in a total of 89 DE-OS-MGs. Furthermore, machine learning was performed and the genes were intersected to obtain 5 candidate OS-IM-related signature genes. The expression levels and ROC analysis of the 5 genes were validated in the GSE96851 and GSE120652 datasets, and 4 genes (CLU, APOH, AMBP, and GPX8) were used as biomarkers (OS-IM-related signature genes) for subsequent analysis. Single-gene GSEA enrichment analysis revealed that the 4 biomarkers were associated with metabolic processes. A miRNA-mRNA network with 123 nodes and 194 relationship pairs was obtained. 49 TFs of 3 biomarkers (APOH, AMBP, and GPX8) and 56 relationship pairs of TFs-mRNA regulatory network also constructed. Searching for therapeutic drugs of 4 biomarkers, a drug-mRNA network of CLU and 3 drugs was constructed. Conclusion: In this study, we combined immune infiltration landscape and oxidative stress based on bioinformatic analysis to screen for diagnostic markers (CLU, APOH, AMBP, and GPX8) of ALF. It provides a new idea and theoretical basis for the therapeutic diagnosis of ALF.
- Open Access
- 13 March 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. Publish Ah (2) , 592-606
Differential response of HBV envelope-specific CD4+ T cells is related to HBsAg loss after stopping nucleos(t)ide analogue therapy
Export Background and Aims: Long-term maintenance of viral control, even HBsAg loss, remains a challenge for chronic hepatitis B (CHB) patients undergoing nucleos(t)ide analogue (NA) discontinuation. This study aimed to investigate the relationship between HBV-specific T cell responses targeting peptides spanning the whole proteome and clinical outcomes in CHB patients after NA discontinuation. Approach and Results: Eighty-eight CHB patients undergoing NA discontinuation were classified as responders (remained relapse-free up to 96 wk) or relapsers (relapsed patients who underwent NA re-treatment for up to 48 weeks and re-achieved stable viral control). HBV-specific T cell responses were detected at baseline and longitudinally throughout follow-up. We found responders had a greater magnitude of HBV Polymerase (Pol)-specific T cell responses than relapsers at baseline. After long-term NA discontinuation, simultaneously enhanced HBV Core- and Pol-induced responses were observed in responders. Particularly, responders with HBsAg loss possessed enhanced HBV Envelope (Env)-induced responses after short and long-term follow-up. Notably, CD4+T cells accounted for the predominance of HBV-specific T cell responses. Correspondingly, CD4-deficient mice showed attenuated HBV-specific CD8+T cell responses, reduced HBsAb-producing B cells, and delayed HBsAg loss; in contrast, in vitro addition of CD4+T cells promoted HBsAb production by B cells . Additionally, interleukin (IL)-9, rather than PD-1 blockade, enhanced HBV Pol-specific CD4+T cell responses. Conclusion: HBV-specific CD4+T cell responses induced by the targeted peptide possess specificities for long-term viral control and HBsAg loss in CHB patients undergoing NA discontinuation, indicating that CD4+T cells specific for distinct HBV antigens may endow with divergent antiviral potential.
- 13 March 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. Publish Ah (2) , 592-606
Open AccessDifferential response of HBV envelope-specific CD4+ T cells is related to HBsAg loss after stopping nucleos(t)ide analogue therapy
Export Background and Aims: Long-term maintenance of viral control, even HBsAg loss, remains a challenge for chronic hepatitis B (CHB) patients undergoing nucleos(t)ide analogue (NA) discontinuation. This study aimed to investigate the relationship between HBV-specific T cell responses targeting peptides spanning the whole proteome and clinical outcomes in CHB patients after NA discontinuation. Approach and Results: Eighty-eight CHB patients undergoing NA discontinuation were classified as responders (remained relapse-free up to 96 wk) or relapsers (relapsed patients who underwent NA re-treatment for up to 48 weeks and re-achieved stable viral control). HBV-specific T cell responses were detected at baseline and longitudinally throughout follow-up. We found responders had a greater magnitude of HBV Polymerase (Pol)-specific T cell responses than relapsers at baseline. After long-term NA discontinuation, simultaneously enhanced HBV Core- and Pol-induced responses were observed in responders. Particularly, responders with HBsAg loss possessed enhanced HBV Envelope (Env)-induced responses after short and long-term follow-up. Notably, CD4+T cells accounted for the predominance of HBV-specific T cell responses. Correspondingly, CD4-deficient mice showed attenuated HBV-specific CD8+T cell responses, reduced HBsAb-producing B cells, and delayed HBsAg loss; in contrast, in vitro addition of CD4+T cells promoted HBsAb production by B cells . Additionally, interleukin (IL)-9, rather than PD-1 blockade, enhanced HBV Pol-specific CD4+T cell responses. Conclusion: HBV-specific CD4+T cell responses induced by the targeted peptide possess specificities for long-term viral control and HBsAg loss in CHB patients undergoing NA discontinuation, indicating that CD4+T cells specific for distinct HBV antigens may endow with divergent antiviral potential.